Janus Henderson Group 13F: Adds $133M to CAH Stake
Janus Henderson Group significantly boosts its investment in Cardinal Health.
Reviewed by automated data checks against the source filing. How we make and check alerts
Janus Henderson Group added 559,450 shares to its stake in Cardinal Health, Inc. ($CAH), a 317.84% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 735,467 shares worth $174.98 million at the end of the quarter.
Since the filing, $CAH is up 2.8% after 1 week, up 16.0% after 1 month and up 30.7% to date (from the $194.32 close on May 15, 2026).
Find the original: Janus Henderson Group 13F filings on SEC EDGAR
CAH
Cardinal Health, Inc.
Key Points
- Janus Henderson Group increased its stake in Cardinal Health by 318%, adding 559,450 shares for a total of 735,467 shares worth $171.4 million.
- Cardinal Health, trading at $233.01, has a market cap of $52.2 billion and a P/E ratio of 34.06, with a 52-week range of $137.75 to $233.6.
- Insider transactions include sales by the CFO and CIO, while analysts maintain strong buy ratings with price targets up to $275.
Get $CAH trade alerts by text
We text you when insiders, Congress or big funds trade $CAH. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
Janus Henderson Group has significantly boosted its stake in Cardinal Health, Inc. (NYSE:CAH), according to its latest 13F filing with the SEC. The investment firm added 559,450 shares, increasing its holdings by 318% to a total of 735,467 shares. The position is now valued at approximately $171.4 million, reflecting holdings as of the end of the reporting period.
Janus Henderson Group vs. the S&P 500
Hypothetical returns from Janus Henderson Group's disclosed trades, not real profit or advice. How we model this.
What Changed in Janus Henderson Group's Cardinal Health Position
Janus Henderson Group made a substantial move by increasing its ownership in Cardinal Health by 318%. The fund now holds 735,467 shares, up from 176,017 shares previously. This change represents an additional investment of 559,450 shares, bringing the total value of its stake to around $171.4 million.
Other Institutional Activity in Cardinal Health
Other major funds have also adjusted their positions in Cardinal Health. BlackRock, Inc. trimmed its holdings by 146,765 shares, ending with 28,494,855 shares valued at $6.02 billion, a 0.5% decrease. In contrast, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, with 15,288,709 and 13,732,309 shares respectively. State Street Corp reduced its stake by 434,712 shares, now holding 12,074,518 shares worth about $2.55 billion, reflecting a 3.5% decrease. Meanwhile, Geode Capital Management, LLC increased its position slightly by 51,519 shares to hold a total of 6,580,532 shares valued at $1.39 billion.
Cardinal Health, Inc. Stock Down 6.2%
Shares of NYSE:CAH traded near $233.01 on Thursday. Cardinal Health boasts a market capitalization of approximately $52.2 billion and a P/E ratio of 34.06. The stock has experienced a 52-week low of $137.75 and a high of $233.6. Its 50-day moving average stands at $203.73, while the 200-day moving average is $197.28. The company has a current ratio of 0.91 and a quick ratio of 0.42, indicating its short-term financial health.
Recent Earnings
Cardinal Health reported revenue of $250.74 billion, with a growth rate of 11%. The company achieved an earnings per share (EPS) of $6.54. Its net margin was 0.62%, and it recorded a return on equity of 34.06%. The next earnings release is scheduled for August 18, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health pays an annual dividend of $2.05, yielding 0.92% with a payout ratio of 31.19%. This provides a steady income stream to its shareholders. The ex-dividend date for the next payout is yet to be announced.
Insider Buying and Selling at Cardinal Health, Inc.
Recent insider activity at Cardinal Health includes a purchase by Patricia Hemingway Hall of 381 shares at an average price of $207.83 on April 15, 2026. On the selling side, Chief Information Officer Michelle Greene sold 2,746 shares at $228.47 on February 27, 2026. Chief Financial Officer Aaron Alt sold shares on multiple occasions, including 2,328 shares at $225.50 on February 18, 2026, and 1,914 shares at $220.79 on February 15, 2026.
Analysts Set New Price Targets
Analysts have maintained their ratings on Cardinal Health. JP Morgan kept a hold rating with a $215 target on May 4, 2026. Citigroup, TD Cowen, and Wells Fargo all maintained buy ratings with targets of $245, $255, and $245 respectively on May 1, 2026. The consensus rating is a strong buy, with a mean target price of $245.27 based on 15 analyst opinions.
About Cardinal Health
Cardinal Health, Inc. is a leading healthcare services and products company based in Dublin, Ohio. It operates through two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides a wide range of products and services to healthcare providers, including hospitals, pharmacies, and clinics. Under the leadership of CEO Jason M. Hollar, Cardinal Health employs over 53,000 people and focuses on delivering efficient healthcare solutions worldwide.
Bottom Line
Janus Henderson Group's significant increase in its stake in Cardinal Health underscores the fund's confidence in the company's prospects. While 13F filings are historical and may not reflect current positions, they offer valuable insight into institutional investment strategies. Investors often track such filings to gauge market sentiment and potential future performance.
Related Filing Alerts
Source: Janus Henderson Group's 13F filing on $CAH (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Janus Henderson Group 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts